Sustained clinical and commercial contracting across technologies and sites driving good growth outlook for CDMO business, the company said.

Revenue: INR1,570 crores, reflecting a 31% year-on-year growth. Gross Margin: 59%, an increase of more than 4% due to better product mix and process improvements. EBITDA: INR389 crores with a margin ...

Laurus Labs Ltd (BOM:540222) reported strong growth in Q3 2025, with revenue increasing by 18% year-on-year, driven by robust demand in the CDMO business. The company maintained healthy gross margins ...

When Dr Satyanarayana Chava started Laurus Labs in 2007, he invested nearly Rs 60 crore of his own money into it. His confidence in its success was neither bravado nor bluster, but defined by his ...

The shares of Laurus Labs dropped more than 3 percent in morning trade on October 24. This comes after the company released its results for the July-September quarter of the financial year 2026.

Hyderabad: Laurus Bio, a subsidiary of Hyderabad-based biopharma player Laurus Labs Ltd, has secured an equity investment of Rs 120 crore from Eight Roads Ventures and F-Prime Capital. Laurus Labs ...

Acquisition of Richcore to add new capabilities. Laurus has announced acquisition of 72% stake in Richcore Lifesciences for Rs 2.5 bn, valuing the business at ~6X FY2021 sales and 15X FY2021 EBITDA.

India’s pharma sector, which has been in the spotlight during the pandemic, has just minted a new billionaire. Satyanarayana Chava, 60, founder and CEO of the $658 million (revenue) Laurus Labs—an ...